• Users Online: 1520
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Contacts Login 
STUDY PROTOCOL
Year : 2016  |  Volume : 1  |  Issue : 3  |  Page : 134-140

L-carnitine for reducing cardio-metabolic risk in patients with obstructive sleep apnea: study protocol of a randomized, double-blind, placebo-controlled trial


1 Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Department of Paediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Sciences, Poznan, Poland
2 Department of Education and Obesity Treatment and Metabolic Disorders, Poznan University of Medical Sciences, Poznan, Poland
3 Department of Human Nutrition and Hygiene, Poznan University of Life Sciences, Poznan, Poland
4 Department of Paediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Sciences, Poznan, Poland
5 Department of Pulmonology, Alergology and Respiratory Oncology, Poznan University of Medical Sciences, Poznan, Poland

Correspondence Address:
Marta Stelmach-Mardas
Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; Department of Paediatric Gastroenterology and Metabolic Disorders, Poznan University of Medical Sciences, Poznan, Poland

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2468-5658.191356

Rights and Permissions

Background: Dyslipidemia and insulin resistance are diagnosed very often in obstructive sleep apnea patients; therefore the novel therapies based on the components involved in lipid and carbohydrates metabolism are still being searched for. L-carnitine may play a positive role in energy metabolism and in the reduction of cardio-metabolic risk factors. The present trial aims to investigate the potential role of L-carnitine in lipid and carbohydrates metabolism with precision non-invasive measurements in obstructive sleep apnea patients. Methods/Design: This ongoing study is a randomized, double-blind, placebo controlled, 2-arm parallel-group trial. A total of 80 eligible patients aged 18-80 with obstructive sleep apnea will be randomized in a 1:1 ratio to receive either placebo (placebo group) or L-carnitine (study group) for 8 weeks. Primary outcome measures are changes in lipid and carbohydrates metabolism. Secondary outcome are changes in non-invasive haemodynamic measurements: central blood pressure, pulse wave velocity and peripheral arterial stiffness (secondary outcome) will be assessed. All outcome measures will be assessed at baseline, 4, 8 weeks, and 6 months post-intervention. Discussion: The novelty of this randomized controlled trial is the supplementation of L-carnitine connected with a mobile application for measuring medication adherence. Combined application of non-invasive haemodynamic measurement with assessment of lipid and glucose metabolism will allow us to examine the potential merit of routine supplementation of L-carnitine in patients suffering from obstructive sleep apnea. Trial registration: ClinicalTrials.gov identifier: NCT02645942, registered on 29 December 2015. Ethics: This trial has been approved by Bioethical Committee at Poznan University of Medical Sciences (approval No. 962/15) and will be performed in accordance with the Declaration of Helsinki, formulated by the World Medical Association. Informed consent: Signed informed consent will be obtained from each patient prior to the trial.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5980    
    Printed341    
    Emailed0    
    PDF Downloaded341    
    Comments [Add]    
    Cited by others 1    

Recommend this journal